Oxcarbazepine extended-release - Supernus Pharmaceuticals

Drug Profile

Oxcarbazepine extended-release - Supernus Pharmaceuticals

Alternative Names: Epliga; OXC-XR; Oxcarbazepine QD; Oxtellar XR; SPN-804

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Supernus Pharmaceuticals
  • Class Antiepileptic drugs; Dibenzazepines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Clinical Phase Unknown Bipolar disorders

Most Recent Events

  • 06 Nov 2017 Clinical trials in Bipolar disorders (PO)
  • 15 Aug 2017 The US District Court for the District of New Jersey rules that TWi Pharmaceuticals has infringed three of Supernus' oxcarbazepine extended-release patents
  • 28 Feb 2017 Supernus plans an exploratory trial for Bipolar disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top